SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (15534)2/20/1998 5:10:00 PM
From: medsunman  Read Replies (1) | Respond to of 32384
 
Henry: I'm trying to get a better handle on the Targretin preclinical results in the rat model for breast cancer. If you could answer these questions, it would be very helpful:

1. How many rats in the test?

2. How many sites involved (if study was done at more than one lab it would be more impressive).

3. How long did tumor regression last?

4. Did 72% tumor regression include some rats with complete response or were they partial responders?

Thanks


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News